Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KALA NASDAQ:OKYO NASDAQ:OVID NASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALAKALA BIO$14.55+0.1%$7.78$2.92▼$15.80$102.16M-1.81187,084 shs367,177 shsOKYOOKYO Pharma$2.26+0.4%$2.69$0.90▼$3.35$85M-0.1124,233 shs50,196 shsOVIDOvid Therapeutics$1.23-4.7%$0.71$0.24▼$1.47$87.47M0.351.91 million shs1.48 million shsRLYBRallybio$0.61+3.9%$0.50$0.22▼$1.24$25.43M-1.1428,566 shs293,345 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALAKALA BIO0.00%+29.68%+103.21%+251.45%+141.69%OKYOOKYO Pharma0.00%-3.83%-28.48%+18.95%+105.45%OVIDOvid Therapeutics0.00%-3.91%+140.47%+286.06%+12.84%RLYBRallybio0.00%+13.42%+19.10%+54.08%-45.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKALAKALA BIO$14.55+0.1%$7.78$2.92▼$15.80$102.16M-1.81187,084 shs367,177 shsOKYOOKYO Pharma$2.26+0.4%$2.69$0.90▼$3.35$85M-0.1124,233 shs50,196 shsOVIDOvid Therapeutics$1.23-4.7%$0.71$0.24▼$1.47$87.47M0.351.91 million shs1.48 million shsRLYBRallybio$0.61+3.9%$0.50$0.22▼$1.24$25.43M-1.1428,566 shs293,345 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKALAKALA BIO0.00%+29.68%+103.21%+251.45%+141.69%OKYOOKYO Pharma0.00%-3.83%-28.48%+18.95%+105.45%OVIDOvid Therapeutics0.00%-3.91%+140.47%+286.06%+12.84%RLYBRallybio0.00%+13.42%+19.10%+54.08%-45.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKALAKALA BIO 3.25Buy$13.00-10.65% DownsideOKYOOKYO Pharma 3.00Buy$7.00209.73% UpsideOVIDOvid Therapeutics 3.17Buy$3.10152.03% UpsideRLYBRallybio 2.00Hold$5.00721.56% UpsideCurrent Analyst Ratings BreakdownLatest RLYB, KALA, OVID, and OKYO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025KALAKALA BIOLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/8/2025OVIDOvid TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.007/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKALAKALA BIO$3.89M26.26N/AN/A$2.02 per share7.20OKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/AOVIDOvid Therapeutics$570K153.45N/AN/A$0.96 per share1.28RLYBRallybio$640K39.74N/AN/A$1.49 per share0.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKALAKALA BIO-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)OKYOOKYO Pharma-$4.71MN/A0.00N/AN/AN/AN/AN/AN/AOVIDOvid Therapeutics-$26.43M-$0.53N/AN/AN/A-574.44%-58.87%-43.18%11/11/2025 (Estimated)RLYBRallybio-$57.78M-$0.94N/AN/AN/A-5,473.33%-71.66%-65.06%11/6/2025 (Estimated)Latest RLYB, KALA, OVID, and OKYO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025OVIDOvid Therapeutics-$0.16-$0.06+$0.10-$0.06$0.09 million$6.27 million8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/A8/7/2025Q2 2025RLYBRallybio-$0.2450-$0.22+$0.0250-$0.22N/A$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKALAKALA BION/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKALAKALA BIO3.192.102.10OKYOOKYO PharmaN/A0.400.40OVIDOvid Therapeutics0.234.724.72RLYBRallybioN/A9.989.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKALAKALA BIO24.61%OKYOOKYO Pharma2.97%OVIDOvid Therapeutics72.24%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipKALAKALA BIO8.32%OKYOOKYO Pharma40.46%OVIDOvid Therapeutics13.10%RLYBRallybio8.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKALAKALA BIO307.02 million6.44 millionNot OptionableOKYOOKYO Pharma737.61 million22.39 millionNot OptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableRLYBRallybio4041.79 million38.15 millionNot OptionableRLYB, KALA, OVID, and OKYO HeadlinesRecent News About These CompaniesRallybio receives $12.5M equity milestone payment from Recursion PharmaceuticalsSeptember 3, 2025 | msn.comRallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 ProgramSeptember 3, 2025 | finance.yahoo.comRallybio Granted Extension for Nasdaq ComplianceAugust 29, 2025 | tipranks.comTD Cowen Reaffirms Their Buy Rating on Rallybio (RLYB)August 12, 2025 | theglobeandmail.comRallybio First Half 2025 Earnings: US$0.43 loss per share (vs US$0.83 loss in 1H 2024)August 9, 2025 | finance.yahoo.comRallybio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 8, 2025 | finance.yahoo.comEvercore ISI Remains a Hold on Rallybio (RLYB)July 16, 2025 | theglobeandmail.comRXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia ... - NasdaqJuly 11, 2025 | nasdaq.comRallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - MorningstarJuly 9, 2025 | morningstar.comMHere's Why Shares in Recursion Pharmaceuticals Surged TodayJuly 8, 2025 | finance.yahoo.comRallybio Sells Interest in REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | finance.yahoo.comRecursion to buy Rallybio’s ownership in jointly developed bone disorder drugJuly 8, 2025 | msn.comRallybio Sells REV102 Program to Recursion PharmaceuticalsJuly 8, 2025 | tipranks.comRallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudyJune 13, 2025 | finance.yahoo.comRallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlookMay 24, 2025 | investing.comRallybio shareholders elect directors, ratify auditorMay 18, 2025 | uk.investing.comRallybio Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 9, 2025 | finance.yahoo.comRallybio to Present at the 2025 Citizens JMP Life Sciences ConferenceApril 29, 2025 | finance.yahoo.comJones Trading Downgrades Rallybio (RLYB)April 15, 2025 | msn.comRallybio downgraded to Hold from Buy at JonesResearchApril 14, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 AI Infrastructure Stocks Powering the Next Tech RevolutionBy Ryan Hasson | August 8, 2025Grab Holdings: Get a Grip Now—Explosive Upside Brewing By Thomas Hughes | August 18, 2025Small Cap, Big Potential: 3 Tech Disruptors You Should Know AboutBy Nathan Reiff | August 22, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025AI Exposure Without the Hype: 3 ETFs That Offer Smarter AI BetsBy Nathan Reiff | August 25, 2025RLYB, KALA, OVID, and OKYO Company DescriptionsKALA BIO NASDAQ:KALA$14.55 +0.02 (+0.14%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$14.48 -0.07 (-0.48%) As of 09/5/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.OKYO Pharma NASDAQ:OKYO$2.26 +0.01 (+0.44%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.26 +0.01 (+0.22%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Ovid Therapeutics NASDAQ:OVID$1.23 -0.06 (-4.65%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.23 +0.00 (+0.33%) As of 09/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.Rallybio NASDAQ:RLYB$0.61 +0.02 (+3.86%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$0.59 -0.02 (-3.55%) As of 09/5/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
